Tag: Evolut Low Risk
ACC 2023: Benefit of TAVI “consistent” over first three years in low risk patients
Three-year results from the Evolut Low Risk trial have shown “durable” benefits of transcatheter...
Two-year Evolut Low Risk trial data shows “very favourable outcomes” for TAVI compared with SAVR
John Forrest (New Haven, USA) sits down with Cardiovascular News to talk about the full two-yea...
PCR e-Course 2020: Evolut Low-Risk trial confirms TAVI is non-inferior to surgery, and establishes it is cost-effective
Full one-year follow-up from the Evolut Low Risk trial has upheld earlier findings from the study, d...
Evolut gets CE mark in low-risk patients and new labelling for bicuspid use
Medtronic has been awarded CE mark for the use of the Evolut transcatheter aortic valve implanta...
TVT 2019: TAVI is “preferred therapy” for low-risk patients
This morning at TVT 2019 (12-15 June, Chicago, USA), in separate presentations, the principal invest...
